Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.17M | -544.00K | 74.71M | -3.10M | -35.74M |
| Total Depreciation and Amortization | 362.00K | 392.00K | 1.65M | 1.65M | 1.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.04M | 7.19M | -72.67M | 72.00K | 23.21M |
| Change in Net Operating Assets | -10.05M | -2.33M | -7.29M | -6.84M | -5.37M |
| Cash from Operations | 5.52M | 4.71M | -3.60M | -8.22M | -16.25M |
| Capital Expenditure | 31.00K | -554.00K | -213.00K | -99.00K | -- |
| Sale of Property, Plant, and Equipment | -141.00K | 589.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 337.00K | -4.61M | 12.15M | 10.64M | -5.47M |
| Cash from Investing | 227.00K | -4.58M | 11.93M | 10.54M | -5.47M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | 0.00 | 0.00 | 0.00 | -372.00K | 0.00 |
| Issuance of Common Stock | 2.55M | 6.53M | 1.38M | 1.98M | 796.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 2.55M | 6.53M | 1.38M | 1.61M | 796.00K |
| Foreign Exchange rate Adjustments | -322.00K | 64.00K | 658.00K | -372.00K | 671.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.97M | 6.73M | 10.37M | 3.56M | -20.25M |